World Congress

Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results

Retrieved on: 
Martedì, Maggio 14, 2024
Haemophilia A, Patient, Cell, Factor VIII, RIGS, WFH, NHP, World government, Sale, MGX, Congress, World Congress, Research, Gene, IPO, PH1, Society, G&A, Vaccine

Furthermore, we see an opportunity to leverage our Hemophilia A program approach as a platform for additional indications requiring large gene integrations.

Key Points: 
  • Furthermore, we see an opportunity to leverage our Hemophilia A program approach as a platform for additional indications requiring large gene integrations.
  • We also plan to present 12-month durability data for Factor VIII expression in the ongoing non-human primate study in the second half of 2024.
  • We plan to demonstrate continued technology advancements at key scientific conferences throughout the remainder of 2024.
  • First quarter 2024 Financial Results:
    Cash Position: Cash, cash equivalents, and available-for-sale marketable securities were $327.4 million as of March 31, 2024, which includes net proceeds of approximately $80.7 million from our IPO completed in February 2024.

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

Retrieved on: 
Martedì, Maggio 7, 2024
Sale, FDA, Table, Safety, Knee, Autumn, Investment, Food, OARSI, Osteoarthritis Research Society International, Conference call, Share repurchase, Osteoarthritis, Research, Depreciation, Bupivacaine, Conference, Webcast, Tax, Patent, Patient, Sciatic nerve block, Medicare, Bank statement, World Congress, GAAP, Growth, Interest, Video game

TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024.

Key Points: 
  • The company expects to fund the share repurchase program using a combination of existing cash reserves and future cash flows.
  • Total revenues were $167.1 million in the first quarter of 2024, versus $160.3 million reported for the first quarter of 2023.
  • First quarter 2024 iovera° net product sales were $5.0 million, versus $4.0 million reported for the first quarter of 2023.
  • Adjusted EBITDA was $44.6 million in the first quarter of 2024, compared to $41.9 million in the first quarter of 2023.

Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week

Retrieved on: 
Giovedì, Aprile 18, 2024
Pain, FDA, Congress, OA, Safety, Biosplice Therapeutics, Osteoarthritis Research Society International, Food, Month, Week, Therapy, Patient, WOMAC, CLK, World Congress, SAN, JSW, Medical device

Preliminary results of OA-07 study, initially reported in November 2023, had demonstrated statistically significant and clinically meaningful improvement in joint structure demonstrated by X-ray results of medial joint space width (medial JSW).

Key Points: 
  • Preliminary results of OA-07 study, initially reported in November 2023, had demonstrated statistically significant and clinically meaningful improvement in joint structure demonstrated by X-ray results of medial joint space width (medial JSW).
  • Biosplice will present its OA-07 results at the Osteoarthritis Research Society International (“OARSI”) World Congress, April 18-21, 2024, in Vienna, Austria.
  • “Patients are desperately seeking a new and safe approach for treating knee osteoarthritis that can provide durable pain relief, improved function, and joint structure benefit,” commented Biosplice Chief Medical Officer, Dr. Yusuf Yazici.
  • The Company observed an unusually high placebo response in this trial compared to published intra-articular OA trials and Biosplice’s prior trials.

Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases

Retrieved on: 
Venerdì, Aprile 26, 2024
Founders Fund, FDA, OA, Patient, Horse, Cell, Notifiable disease, Animal, OARSI, Osteoarthritis Research Society International, Infection, Entrepreneurship, Research, Pathology, Artificial intelligence, Disease, Human, Novartis, Therapy, Ageing, Pulmonary fibrosis, Osteoarthritis, Gene, Biology, Drug discovery, Longevity, World Congress, MASH, Heart failure, Pharmaceutical industry

SAN FRANCISCO, April 26, 2024 /PRNewswire/ -- Gordian Biotechnology, an in vivo drug discovery and development company, today announced its platform that enables patient predictive, in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging at a scale never before possible.

Key Points: 
  • Gordian's Osteoarthritis (OA) program has screened hundreds of therapies in horses that acquired OA naturally and advanced dozens of therapies into human ex vivo validation studies.
  • In proof of concept experiments during initial development, Gordian introduced a pooled library of 50 gene therapies into a mouse model of metabolic-associated steatohepatitis (MASH).
  • The therapies were evaluated using the company's proprietary in vivo screening platform, which successfully recapitulated 13 out of 16 clinical outcomes for targets where clinical data exists.
  • Mosaic Screening™ is pooled in vivo screening that tests hundreds of therapies simultaneously in a single sick animal, the Patient Avatar.

Peter Eckes, Former CTO of BASF Agricultural Solutions, to Chair Harpe Bioherbicide Board

Retrieved on: 
Mercoledì, Aprile 17, 2024
Congress, Peter, University, UN, Seed, University of Western Australia, Eckes, BASF, Organic, North Carolina State University, Life, Farmer, Desiccation, Crop protection, Weed control, Associate, World Congress, Harpe, Management

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 /PRNewswire/ -- Harpe Bioherbicide Solutions, Inc., an agricultural technology company focused on providing natural and sustainable herbicide solutions, announced today that Dr. Peter Eckes, former President of BASF leading Crop Protection R&D, Seed and Trait R&D and Regulatory in the Agricultural Solutions division, has joined its board and will serve as board chairperson.

Key Points: 
  • "Harpe has both a compelling value proposition and strong business plan to bring new and natural weed control innovations to life," said Eckes.
  • Eckes assumes board leadership from Aidan J. Connolly, President of AgriTech Capital, who will remain as a Harpe Bioherbicide board member.
  • Additional Harpe Bioherbicide board members include CEO Buckner; Kip Tom, CEO of Tom Farms and former UN Ambassador; Robb Fraley, former CTO for Monsanto Co.; Chad Brommer, Harpe Bioherbicide co-founder and CTO; and Daniel Pepitone, Harpe Bioherbicide co-founder and COO.
  • Those attending are invited to visit Booth #22 to learn more about Harpe Bioherbicide formulations.

Peter Eckes, Former CTO of BASF Agricultural Solutions, to Chair Harpe Bioherbicide Board

Retrieved on: 
Mercoledì, Aprile 17, 2024
Congress, Peter, University, UN, Seed, University of Western Australia, Eckes, BASF, Organic, North Carolina State University, Life, Farmer, Desiccation, Crop protection, Weed control, Associate, World Congress, Harpe, Management

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 /PRNewswire/ -- Harpe Bioherbicide Solutions, Inc., an agricultural technology company focused on providing natural and sustainable herbicide solutions, announced today that Dr. Peter Eckes, former President of BASF leading Crop Protection R&D, Seed and Trait R&D and Regulatory in the Agricultural Solutions division, has joined its board and will serve as board chairperson.

Key Points: 
  • "Harpe has both a compelling value proposition and strong business plan to bring new and natural weed control innovations to life," said Eckes.
  • Eckes assumes board leadership from Aidan J. Connolly, President of AgriTech Capital, who will remain as a Harpe Bioherbicide board member.
  • Additional Harpe Bioherbicide board members include CEO Buckner; Kip Tom, CEO of Tom Farms and former UN Ambassador; Robb Fraley, former CTO for Monsanto Co.; Chad Brommer, Harpe Bioherbicide co-founder and CTO; and Daniel Pepitone, Harpe Bioherbicide co-founder and COO.
  • Those attending are invited to visit Booth #22 to learn more about Harpe Bioherbicide formulations.

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Retrieved on: 
Giovedì, Aprile 11, 2024
OA, Fluticasone, Pain, Patient, Knee, Randomness, OARSI, Osteoarthritis Research Society International, Osteoarthritis, Abstract, TSX, Pharmacokinetics, MRI, Diabetes, World Congress, Pharmaceutical industry

VICTORIA, BC, April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024.

Key Points: 
  • VICTORIA, BC, April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024.
  • The meeting is being held in Vienna, Austria from April 18-21, 2024.
  • In combination with our pre-clinical and MRI results, these data suggest a potential best-in-class candidate in terms of managing cartilage health."
  • Poster Title: Pharmacokinetics of EP-104IAR Long-lasting Fluticasone Propionate for Intra Articular Injection in 163 Subjects from SPRINGBOARD, a Phase 2 Study in Knee Osteoarthritis.

Metagenomi to Present at Upcoming Scientific Meetings

Retrieved on: 
Lunedì, Aprile 8, 2024
Congress, Patient, Gene, World Congress, World Federation of Hemophilia, MD, World government, Society, Cell, MGX, WFH, Annual general meeting, Pharmaceutical industry

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Key Points: 
  • -   Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024
    -   Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024
    EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Retrieved on: 
Mercoledì, Marzo 13, 2024
Knee, Congress, Biologics license application, Patient, ATMP, Research, World Congress, OARSI, European Medicines Agency, WOMAC, Osteoarthritis Research Society International, KOOS, Drug development, Safety, Pain, Vasopressin receptor 2, DVD-Audio, Food, Osteoarthritis, FDA, BLA, Pharmaceutical industry

TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra), for the treatment of osteoarthritis of the knee.

Key Points: 
  • PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts.
  • Preliminary 36-week data were presented at the Osteoarthritis Research Society International (OARSI) 2023 World Congress, the premier annual international forum in osteoarthritis research and treatment.
  • The 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.
  • PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

Deputy Minister of Ukraine, Nataliia Kalmykova, will be speaking at the LA Convention Center this week

Retrieved on: 
Martedì, Marzo 12, 2024
Karma, SBMT, Brain, Congress, Brain mapping, Neuroscience, Neurology, Multiple sclerosis, Alzheimer's disease, Ophthalmology, Doe, Knowledge, Los Angeles Convention Center, Associate, Journal, Loma Linda University, Disease, Military medicine, World Congress, AI, Cadaver, Neuro-oncology, Society, Michelson Medical Research Foundation, Journal of Alzheimer's Disease, NASA, Neuroelectrics, Regenerative medicine, Therapy, Spine, Multimedia, Springer Nature, B cell, Neurosurgery

Deputy Minister of Ukraine, Nataliia Kalmykova, will be amongst keynotes ; Ukrainian neurosurgeons from the frontline will also be speaking about combat casualty care and participate in the convention in person.

Key Points: 
  • Deputy Minister of Ukraine, Nataliia Kalmykova, will be amongst keynotes ; Ukrainian neurosurgeons from the frontline will also be speaking about combat casualty care and participate in the convention in person.
  • Since the beginning of the war in Ukraine, SBMT has been supporting Ukrainian doctors with training and medical equipment.
  • The SBMT World Congress is renowned for its comprehensive program, offering a diverse range of presentations, hands-on workshops, Bioskills cadaver labs, and an expansive exhibition hall.
  • Attendees can expect to engage with cutting-edge research, innovative technologies, and expert insights that are shaping the future of neurosciences and neurotechnology.